Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson's disease

Neurochemistry International

Volumn 57, Issue 3, 2010, Pages 227-234

  Arguelles S ^a   Venero, J L ^a   Garcia Rodriguez S ^a   Tomas Camardiel, M ^a   Ayala, A ^a   Cano, J ^a   Machado, A ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Haptoglobin; LPS; Parkinson's disease; Prostaglandin D synthase; Transthyretin

Indexed keywords

HAPTOGLOBIN; LIPOPOLYSACCHARIDE; PREALBUMIN; PROSTAGLANDIN D SYNTHASE; ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DOPAMINE; ISOMERASE; LIPOCALIN; OXIDOPAMINE; PROSTAGLANDIN R2 D-ISOMERASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RAT; SUBSTANTIA NIGRA; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMICALLY INDUCED; EARLY DIAGNOSIS; HEMISPHERIC DOMINANCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MASS SPECTROMETRY; METABOLISM; MICROINJECTION; PATHOLOGY; PHYSIOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; DOPAMINE; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FUNCTIONAL LATERALITY; HAPTOGLOBINS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; LIPOPOLYSACCHARIDES; MICROINJECTIONS; OXIDOPAMINE; PARKINSON DISEASE; PREALBUMIN; RATS; RATS, WISTAR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 77955096230     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.05.014     Document Type: Article

References (46)

1. Arduino D.M., Esteves A.R., Cardoso S.M., Oliveira C.R. Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: relevance to Parkinson's disease. Neurochem. Int. 2009, 55:341-348.
2. Beuckmann C.T., Lazarus M., Gerashchenko D., Mizoguchi A., Nomura S., Mohri I., Uesugi A., Kaneko T., Mizuno N., Hayaishi O., Urade Y. Cellular localization of lipocalin-type prostaglandin D synthase (beta-trace) in the central nervous system of the adult rat. J. Comp. Neurol. 2000, 428:62-78.
3. Castano A., Herrera A.J., Cano J., Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 2002, 81:150-157.
4. Castano A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 1998, 70:1584-1592.
5. Chen L.W., Wang Y.Q., Wei L.C., Shi M., Chan Y.S. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS & Neurol. Disord. Drug Targets 2007, 6:273-281.
6. Cid M.C., Grant D.S., Hoffman G.S., Auerbach R., Fauci A.S., Kleinman H.K. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J. Clin. Invest. 1993, 91:977-985.
7. Consiglio A.R., Lucion A.B. Technique for collecting cerebrospinal fluid in the cisterna magna of non-anesthetized rats. Brain Res. 2000, 5:109-114.
8. Costa-Mallen P., Checkoway H., Zabeti A., Edenfield M.J., Swanson P.D., Longstreth W.T., Franklin G.M., Smith-Weller T., Sadrzadeh S.M. The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am. J. Med. Genet. 2008, 147B:216-222.
9. de Kleijn D.P., Smeets M.B., Kemmeren P.P., Lim S.K., Van Middelaar B.J., Velema E., Schoneveld A., Pasterkamp G., Borst C. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J. 2002, 16:1123-1125.
10. do Nascimento C.O., Hunter L., Trayhurn P. Regulation of haptoglobin gene expression in 3T3-L1 adipocytes by cytokines, catecholamines, and PPARgamma. Biochem. Biophys. Res. Commun. 2004, 313:702-708.
11. Eller M., Williams D.R. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat. Rev. Neurol. 2009, 5:561-570.
12. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 2007, 205:295-312.
13. Friedrichs W.E., Navarijo-Ashbaugh A.L., Bowman B.H., Yang F. Expression and inflammatory regulation of haptoglobin gene in adipocytes. Biochem. Biophys. Res. Commun. 1995, 209:250-256.
14. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology 2009, 72:S27-S31.
15. Hagen G.A., Elliott W.J. Transport of thyroid hormones in serum and cerebrospinal fluid. J. Clin. Endocrinol. Metabol. 1973, 37:415-422.
16. Herbert J., Wilcox J.N., Pham K.T., Fremeau R.T., Zeviani M., Dwork A., Soprano D.R., Makover A., Goodman D.S., Zimmerman E.A. Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology 1986, 36:900-911.
17. Herrera A.J., Castano A., Venero J.L., Cano J., Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 2000, 7:429-447.
18. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S9-S15.
19. Hoffmann A., Conradt H.S., Gross G., Nimtz M., Lottspeich F., Wurster U. Purification and chemical characterization of beta-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J. Neurochem. 1993, 61:451-456.
20. Ingenbleek Y., Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu. Rev. Nutr. 1994, 14:495-533.
21. Kang X., Chen J., Xu Z., Li H., Wang B. Protective effects of Ginkgo biloba extract on paraquat-induced apoptosis of PC12 cells. Toxicol. In Vitro 2007, 21:1003-1009.
22. Mazur-Kolecka B., Frackowiak J., Wisniewski H.M. Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 1995, 698:217-222.
23. Mendel C.M., Weisiger R.A., Jones A.L., Cavalieri R.R. Thyroid hormone-binding proteins in plasma facilitate uniform distribution of thyroxine within tissues: a perfused rat liver study. Endocrinology 1987, 120:1742-1749.
24. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000, 23:S8-19.
25. Pan J., Xiao Q., Sheng C.Y., Hong Z., Yang H.Q., Wang G., Ding J.Q., Chen S.D. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem. Int. 2009, 54:418-425.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego.
27. Piccini P., Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2004, 3:284-290.
28. Puskas L.G., Kitajka K., Nyakas C., Barcelo-Coblijn G., Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1580-1585.
29. Quaye I.K. Haptoglobin, inflammation and disease. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:735-742.
30. Revuelta M., Venero J.L., Machado A., Cano J. Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes. Glia 1997, 21:204-216.
31. Rigau V., Morin M., Rousset M.C., de Bock F., Lebrun A., Coubes P., Picot M.C., Baldy-Moulinier M., Bockaert J., Crespel A., Lerner-Natoli M. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007, 130:1942-1956.
32. Rite I., Arguelles S., Venero J.L., Garcia-Rodriguez S., Ayala A., Cano J., Machado A. Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. J. Neurosci. Res. 2007, 85:3607-3618.
33. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 2000, 21:1227-1234.
34. Saso L., Leone M.G., Sorrentino C., Giacomelli S., Silvestrini B., Grima J., Li J.C., Samy E., Mruk D., Cheng C.Y. Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential marker for brain tumor. Biochem. Mol. Biol. Int. 1998, 46:643-656.
35. Schwarzman A.L., Gregori L., Vitek M.P., Lyubski S., Strittmatter W.J., Enghilde J.J., Bhasin R., Silverman J., Weisgraber K.H., Coyle P.K. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:8368-8372.
36. Tansey M.G., McCoy M.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 2007, 208:1-25.
37. Tolosa E., Gaig C., Santamaria J., Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009, 72:S12-S20.
38. Tomas-Camardiel M., Rite I., Herrera A.J., de Pablos R.M., Cano J., Machado A., Venero J.L. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 2004, 16:190-201.
39. Urade Y., Hayaishi O. Prostaglandin D synthase: structure and function. Vitam. Horm. 2000, 58:89-120.
40. Venero J.L., Revuelta M., Atiki L., Santiago M., Toms-Camardiel M.C., Cano J., Machado A. Evidence for dopamine-derived hydroxyl radical formation in the nigrostriatal system in response to axotomy. Free Radic. Biol. Med. 2003, 34:111-123.
41. Venero J.L., Revuelta M., Cano J., Machado A. Time course changes in the dopaminergic nigrostriatal system following transection of the medial forebrain bundle: detection of oxidatively modified proteins in substantia nigra. J. Neurochem. 1997, 68:2458-2468.
42. Verma R., Nehru B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Neurochem. Int. 2009, 55:369-375.
43. Watanabe C.M., Wolffram S., Ader P., Rimbach G., Packer L., Maguire J.J., Schultz P.G., Gohil K. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6577-6580.
44. Watanabe K., Urade Y., Mader M., Murphy C., Hayaishi O. Identification of beta-trace as prostaglandin D synthase. Biochem. Biophys. Res. Commun. 1994, 203:1110-1116.
45. Wersinger C., Sidhu A. Inflammation and Parkinson's disease. Curr. Drug Targets Inflamm. Allergy 2002, 1:221-242.
46. Zheng W., Deane R., Redzic Z., Preston J.E., Segal M.B. Transport of l-[125I]thyroxine by in situ perfused ovine choroid plexus: inhibition by lead exposure. J. Toxicol. Environ. Health. Part A 2003, 66:435-451.